Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR CLEAN-MED
NL-OMON53150Phase 3Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin and heparin in ischemic stroke and brain infarction, sponsored by Erasmus MC. Primary endpoint: Modified Rankin Scale at 90 days. Started Jan 2018; status: active, not recruiting.
02
Drugs
aspirinheparin
03
Conditions
ischemic strokebrain infarction
Beyond the preview
Go deeper on NL-OMON53150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53150.